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Bryostatin 1, a novel antineoplastic agent and protein kinase C activator,
induces human myalgia and muscle metabolic defects: a31P magnetic
resonance spectroscopic study
PF Hickman', GJ Kemp', CH Thompson', AJ Salisbury2, K Wade', AL Harris2 and GK
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'MRC Biochemical and Clinical Magnetic Resonance Unit, Oxford Radcliffe Hospital, Oxford, UK; 2ICRF Clinical Oncology
Unit, Churchill Hospital, Oxford, UK.
Summary Bryostatin 1, a novel antineoplastic agent and protein kinase C (PKC) activator, has been found to
induce myalgia (muscle pain) 48 h after administration in clinical trials. This is the dose-limiting toxicity and
has restricted the duration of therapy in phase I trials. To investigate the mechanisms and try to increase
toleration of the drug, we studied calf muscle metabolism of 14 patients at rest and during exercise and
subsequent recovery using 31P magnetic resonance spectroscopy (MRS) before and 4 h, 48 -72 h and 1-2
weeks following bryostatin therapy. In resting muscle there was a significant (P<0.001) increase in the
phosphodiester/adenosine 5'-triphosphate (PDE/ATP) ratio 48 h post bryostatin and in patients with myalgia
compared with pre-bryostatin control studies. Following exercise, patients with myalgia showed significantly
slower phosphocreatine (PCr) and ADP recovery half-time (P<0.05) suggesting impaired mitochondrial
(oxidative) energy production, possibly due to a direct effect on the mitochondria or secondary to reduced
blood flow. The apparent proton efflux rate following exercise was significantly reduced 4 h after bryostatin
(P<0.05), suggesting reduced blood flow. The rate of post-exercise reoxygenation was studied in four patients
by near-infrared spectroscopy 4 h post bryostatin. In three of these the rate was reduced, consistent with
reduced muscle blood flow. Bryostatin 1 appeared to cause a long-lasting impairment of oxidative metabolism
and proton washout from muscle, consistent with a vasoconstrictive action. Thus these studies provide
evidence for two mechanisms of the dose-limiting toxicity for bryostatin. Prospective studies on the use of
vasodilators to improve the tolerance of the drug should be carried out.
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Bryostatin 1 is the prototype of a novel family of potent
activators of protein kinase C (PKC) (Berkow and Kraft,
1985), isolated from the marine invertebrate Bugula neritina
(Pettit et al., 1982). Following the display of potent antineo-
plastic actions in cell lines and animal models (Hornung et
al., 1992), mainly ascribed to cell signalling modifications,
clinical phase I trials exploring potential antineoplastic
actions in patients were commenced. Difficulties arose
because patients experienced myalgia (generalised muscle
pain), characteristically starting 48 h after bryostatin admin-
istration. The pain involved all muscle groups, especially
calves and thighs, but also including retro-orbital muscles.
The pain included both muscle stiffness and tenderness, and
could be relieved partly by hot baths and movement. Treat-
ment therefore had to be withdrawn in 17% of patients
(Philip et al., 1993) and myalgia remains the dose-limiting
toxicity, both for single injections and for chronic adminis-
tration (Prendiville et al., 1988). A variety of analgesics,
including morphine and steroids, were ineffective in reducing
this pain, which was not associated with an elevation of
serum creatine kinase or with urine myoglobin excretion, and
did not correlate in time with observed increases in cir-
culating cytokine concentrations (Philip et al., 1993). The
mechanisms of the pain remain unknown (Philip et al., 1993).
To try and overcome the dose-limiting toxicity and enable
continuous use of this novel agent, a series of magnetic
resonance spectroscopy (MRS) studies was carried out.
Muscle pain is perceived following stimulation of muscle
pain receptors (nociceptors), and can be a consequence of
muscle cell destruction, involvement of intramuscular blood
vessels, or defective energy metabolism, as found in painful
myopathies (Mills and Edwards, 1983; Morgan-Hughes,
1987). Owing to their carcinogenic nature, other PKC
activators such as the phorbol esters have not been invest-
igated in humans. Despite this, the consequences of PKC
activation in animal muscle appear to be relatively diverse,
resulting in stimulated prostaglandin production, histamine
and serotonin release (Naka et al., 1983; Halenda et al., 1985;
Mobley and Tai, 1985), smooth muscle vasoconstriction
(Mori et al., 1990), cardiac depression, coronary vasocon-
striction and abnormal energy metabolism in the isolated
perfused heart (Watson and Karmazyn, 1991), and myofibri-
llar disorganisation in skeletal muscle (Doetschman and
Eppenberger, 1984; Moses and Claycomb, 1989).
The non-invasive technique of 31P MRS has been exten-
sively used in the investigation of skeletal muscle energy
metabolism. In particular, it can detect abnormalities of
glycogenolytic and oxidative ATP synthesis as well as of net
proton efflux from the cell (Kemp and Radda, 1994). We
therefore carried out a 3'P MRS exercise/recovery study of
calf muscle to search for evidence in bryostatin-induced
myalgia-of either mitochondrial dysfunction per se, or of
abnormal mitochondrial function and net proton efflux
secondary to vasoconstriction. To assist in distinguishing
these possible abnormalities, in some patients we also studied
reoxygenation times after ischaemic exercise in forearm mus-
cle in vivo using near-infrared spectroscopy.
Materials and methods
Magnetic resonance spectroscopy studies
Thirty-five studies were performed on 14 patients, six men,
eight women (age 39-75 years, mean 52 years) recruited
from a Cancer Research Campaign phase I clinical trial of
Bryostatin 1 in disseminated malignancies, unresponsive to
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Table I Clinical details ofpatients studied
Patient Age Sex Diagnosis Myalgia
1 42 F Maxillary carcinoma Grade 3
2 63 F Melanoma Grade 1-3
3 61 F Bladder adenocarcinoma Grade 2
4 47 F Breast carcinoma Grade 0
5 70 F Melanoma Grade 1
6 56 F Squamous cell lung carcinoma Grade 1
7 46 F Melanoma Grade 1-2
8 45 F Melanoma Grade 2
9 43 M Renal adenocarcinoma Grade 1-2
10 46 M Bronchial adenocarcinoma Grade 0
11 39 M Melanoma Grade 1-2
12 54 M Melanoma Grade 1
13 46 M Melanoma Grade 0
14 75 M Melanoma Grade 2
Myalgia: Grade 0, no pain; grade 1, mild pain not requiring analgesia; grade 2,
moderately severe pain with irregular analgesia; grade 3, moderate to severe pain
requiring non-opiate analgesia (Philip et al., 1993). Dose = 25 jgm-2 in all
patients except 501tg m-2 in patient 1.
conventional treatment. Clinical details are given in Table I.
Informed consent was obtained from all subjects and the
work performed with ethics committee approval. Treatment
consisted of 25 Lg m2 bryostatin by intravenous infusion
over 1 h (50 iLg m-2 bryostatin in one patient). This was
administered once a week for 3 weeks with no treatment
during the 4th week, followed by 3 more treatment weeks (a
total of six doses per course of treatment). Thirteen MRS
studies were obtained before bryostatin therapy, and early
and late post-bryostatin studies were organised to study mus-
cle at 4-6 h (n = 10) usually before the occurrence of myal-
gia and at 48-72 h (n = 7) when myalgia was present. Each
timed group contained no more than one study from each
patient. Owing to clinical or technical difficulties two patients
were studied at 24 h and three patients 1-2 weeks after
bryostatin. Of all the above studies, 11 were obtained in the
presence of myalgia: these were also combined as a 'myalgia'
group, including single data sets from three patients and two
data sets from four patients.
Subjects were placed in a 90 cm wide-bore 2T super-
conducting magnet (Oxford Instruments, Oxford, UK) inter-
faced to a Bruker spectrometer (Bruker, Coventry, UK) with
the right calf overlying a 6-cm-diameter surface coil. Data
were collected with an 80,ls pulse width and a 2 s interpulse
delay. Two 64-scan spectra were acquired from the muscle at
rest. Patients exercised by performing plantar flexion of the
right ankle lifting a weight of 10% lean body mass (obtained
from skinfold thickness using standard tables; Durnin and
Womersley, 1974). After 5 min of exercise, the weight was
increased by 2% lean body mass every 1.25 min until the
patient complained of fatigue or rapid PCr depletion was
observed. Thirty-two scan spectra (1.25 min) were collected
throughout exercise, and recovery was monitored by collec-
ting four 8-scan spectra, four 16-scan, three 32-scan and two
64-scan spectra (13 min of recovery in total).
Signals were detected from inorganic phosphate (Pi), phos-
phocreatine (PCr), adenosine triphosphate (ATP), phos-
phomonoesters (PME) and phosphodiesters (PDE), and were
processed by exponential multiplication and Fourier transfor-
mation. Signal intensities were obtained by using a time
domain fitting programme (VARPRO, R. de Beer, Utrecht,
Holland), which identifies a specified number of exponen-
tially decaying signals in the free induction decay acquired
from the muscle, using prior knowledge of the expected
amplitudes, relative positions and widths of the peaks to be
fitted. Cytosolic concentrations of Pi and PCr in mm (i.e.
mmol l-' intracellular water) were calculated from the
relative signal intensities of Pi, PCr and ATP corrected for
differential magnetic saturation and assuming an intracellular
ATP concentration in resting muscle of 8.2mM. Cytosolic
pH was determined from the chemical shift of Pi from PCr
(Arnold et al., 1984) and free [ADP] (JAM) in the cytosol was
calculated from pH and [PCr] and the equilibrium constant
of the creatine kinase reaction, assuming a normal [total
creatine] of 42.5 mM (Arnold et al., 1984; Veech et al., 1979).
During exercise [PCr] is more conveniently expressed as PCr/
(PCr+Pi), which corrects for signal loss due to movement
with respect to the coil.
For kinetic analysis, data were assigned to the midpoint of
the acquisition interval. The decrease in pH and PCr during
the acquisition of the last exercise spectrum (which provides
part of the data used for calculation of initial PCr recovery
and proton efflux) was corrected for by linear extrapolation
of pH and PCr/(PCr+Pi) from the midpoints of the last two
exercise spectra to the end of the last exercise spectrum.
During exercise, ATP is produced by net hydrolysis of PCr
which removes protons, glycogenolysis to lactic acid (which
generates 1.5 protons per ATP) and oxidative phosphory-
lation, which produces a negligible proton load (Kemp and
-Radda, 1994; Kemp et al., 1994). Over the first exercise
interval (i.e. from rest state to the first data point in exercise,
t = 0.5 min), we can calculate the rate of non-oxidative ATP
synthesis, which is a good estimate of the total rate of ATP
turnover at the start of exercise (Kemp et al., 1994), as the
sum of the rates of net PCr depletion and of glycogenolytic
ATP synthesis. Glycogenolytic ATP synthesis is estimated at
1.5 times the sum ofthe rates at which protons are consumed
by net hydrolysis of PCr and taken up by cellular buffers
(over this interval, where pH changes are small, it can be
assumed that proton efflux is negligible). Thus the total rate
of non-oxidative ATP synthesis is given by
- (d[PCr]/dt){1 + 1.51[1 + 10(pH-6.75)]}_ l.5p(dpH/dt)
where 6.75 is the pKofphosphoric acid and P is the cytosolic
buffer capacity (Kemp and Radda, 1994; Kemp et al., 1994).
Mitochondrial ATP synthesis was assessed from the
recovery kinetics of [PCr] after exercise. The half-time of PCr
recovery, which is sensitive to abnormalities of mitochondrial
metabolism (Arnold et al., 1984), was calculated by graphical
interpolation. To analyse mitochondrial function in more
detail we also calculated the initial rate of PCr resynthesis
(d[PCrJ/dt) by comparing [PCr] at the end of exercise and at
the first data point in recovery (t = 0.13 min). This is a direct
estimate of the rate (Q) of mitochondrial ATP synthesis,
which is driven by cytosolic [ADP] according to a hyperbolic
relationship (Kemp et al., 1993a). To quantify mitochondrial
function, this relationship was used together with the
measured initial PCr recovery rate to calculate the apparent
maximum rate of oxidative ATP synthesis as
Qmax = (d[PCr]/dt){l + Km/[ADP]}
where Ki, the [ADP] for half-maximal oxidative ATP syn-
thesis, is assumed to be normal (30itM) (Kemp et al.,
1993a,b).
The recovery of pH after exercise depends on the proton
efflux, and this was quantified by using changes in pH andBryostaln-induced myalgia
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[PCr] at the start of recovery to calculate the initial rate of
proton efflux in recovery (Kemp and Radda, 1994; Kemp et
al., 1994); this is taken as the sum of the rates at which
protons are released by PCr resynthesis and made available
from the cellular buffers. The calculation (Kemp and Radda,
1994; Kemp et al., 1994) resembles the analysis of initial
exercise described above; the proton efflux rate is given by
(d[PCr]/dt)/[l + IO(pH -6.75)] + P(dpH/dt)
in which the calculation is performed for the first two inter-
vals of recovery (t = 0- 0.13 and 0.13 - 0.47 min), and the
results averaged.
Near-infrared spectroscopy studies
Limb reoxygenation during exercise and recovery was studied
in the forearm flexor muscles with near-infrared spectroscopy
(Runman, NIM, Philadelphia, PA, USA), using the diff-
erence in absorption characteristics between deoxyhaemo-
globin and oxyhaemoglobin at two different wavelengths (760
and 840 nm) to estimate the relative deoxygenation of
haemoglobin (Wilson et al., 1989). We performed 12 studies
on five patients, of which five were before treatment, four at
4 h and three at 48-72 h following treatment with bryostatin.
The 'Runman' study took place immediately before the MRS
study. A probe emitting light in the near infrared was placed
upon the patient's forearm overlying the flexor muscles. Foll-
owing calibration, patients exercised their flexor muscles by
repetitively pulling against a constant weight of 0.75 kg at
40min'1. After exercising for about 1-2min, a cuff was
inflated around the upper arm to 20 mmHg above the patient's
systolic blood pressure. Exercise was continued until fatigue
started to be experienced, then measurements were continued
until readings stabilised. After steady state was achieved, the
cuff was released and the recovery half-time was calculated
by measuring the time taken to reach 50% limb reoxygena-
tion.
Data analysis
Results were analysed in two ways: dividing the data accord-
ing to the time intervals following bryostatin (i.e. ten studies
at 4h, seven at 48-72 h and three at 1-2 weeks), and
dividing according to the presence or absence ofmyalgia (the
former group containing one study performed at 4 h, seven
at 48-72 h and three at 1-2 weeks). Student's paired t-test
was used to assess the statistical significance of the results.
Although it was not possible to obtain studies at each time
interval for all the patients, in the tables, results are displayed
as overall means ± s.e.m., containing all available data points
for each group.
Results
31P MRS results
In resting muscle, no differences were observed at 4 h post-
bryostatin, though PDE/ATP was significantly increased by
100 ± 29% at 48 h and by 87 ± 28% for the whole myalgic
group (Table II). During exercise, there was no significant
difference between the groups with respect to the initial rate
of ATP synthesis, the duration or the end-exercise state
(Table III).
Results during recovery from exercise are shown in Table
IV. The initial PCr recovery rate was significantly slower by
33 ± 12% 4-6 h post bryostatin and by 35 ± 14% in the
myalgic group, although no difference in PCr recovery half-
time could be demonstrated.
The ADP recovery half-times were significantly slower by
30 ± 10% at 48-72 h and by 45 ± 17% at 1-2 weeks post-
bryostatin, with an overall reduction of 36 ± 9% in the myal-
gic group. The calculated maximum rate of oxidative ATP
synthesis, Qmax was significantly reduced by 28 ± 13% at 4 h
post bryostatin and by 34 ± 12% in the myalgic group. The
Table II Resting metabolite values obtained from 31p MRS
Time Presence of
Control 4 h 48-72h 1-2 weeks myalgia
pH 7.01 + 0.01 7.00 ± 0.01 7.01 ± 0.01 7.01 ± 0.0l*a 7.01 ± 0.02
Pi/ATP 0.34 ± 0.02 0.34 ± 0.02 0.33 ± 0.03 0.35 ± 0.04 0.33 ± 0.02
PCr/ATP 3.3 0.1 3.2 ± 0.1 3.1 ± 0.1 3.0 ± 0.4 3.0 ± 0.1
ADPJuM) 16±2 17±3 20±3 23±9 21 ±2
PME/ATP 0.09 + 0.03 0.07 ± 0.03 0.07 ± 0.04 0.10 ± 0.08 0.08 ± 0.03
PDE/ATP 0.15 + 0.03 0.15 ± 0.03 0.29 ± 0.04** 0.23 ± 0.11 0.25 ± 0.04**
Number of studies 13 10 7 3 11
in group
pH andmetabolite ratios from muscle spectra obtained atrestare shown giving the overall mean ± s.e.m. forall studies
in each category. Student's paired t-test compared values from each individual's post-bryostatin study with their
pre-bryostatin study (control) (*P<0.05, **P <0.01, ***P <0.001). Each timed group contains no more than one study
fromeachpatient. Themyalgiagroupconsistsofallthestudiesobtainedinthepresenceofmyalgiaandincludessingledata
setsfrom threepatientsandtwodatasetsfromfourpatients.aForthesethreestudiesmeancontrolpHwas6.99 ± 0.01 and
post-bryostatin pH was 7.01 ± 0.01.
Table III 31P MRS results from exercising muscle
Time Presence of
Control 4 h 48-72 h 1-2 weeks myalgia
End ofexercise pH 6.77 ± 0.05 6.81 ± 0.08 6.83 ± 0.09 6.91 ± 0.02 6.86 ± 0.05
End of exercise ADP uM) 69 7 66 9 77 14 67 12 76 9
End ofexercise PCr/(PCr + Pi) 0.36 ± 0.03 0.43 ± 0.05 0.42 ± 0.05 0.50 ± 0.06 0.45 ± 0.03
Exercise duration (min) 7.0 ± 0.8 7.6 ± 1.0 6.6 ± 1.0 7.2 ± 0.5 6.9 ± 0.6
Initial non-oxidative ATP 18 ± 2 15 ± 2 19 ± 4 12 ± 2 17 ± 3
synthesis rate (mM min-')
Number of studies in group 13 10 7 3 11
pHandmetabolite ratiosobtainedattheendofexerciseareshown.Thelengthoftimespentexercisingisstated. Resultsobtainedat
thebeginningofexercise were used to derive thenon-oxidative ATPsynthesis rate. Resultsare shown asoverall mean ± s.e.m. forall
studies in each category. Student's paired t-test compared values from each individual's post-bryostatin study with their
pre-bryostatin study (control) (*P <0.05, ** P <0.01, ***P <0.001). Each timed group contains no more than one study from each
patient. The myalgia group consists ofall the studies obtained in the presence ofmyalgia and includes single data sets from three
patients and two data sets from four patients.Bryostan-indWuced myalgia
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Table IV 31P MRS results during recovery from exercise
Time Presence of
Control 4 h 48-72h 1-2 weeks myalgia
PCr recovery half-time (s) 34 4 38 7 34 7 32 5 32 4
ADP recovery half-time (s) 13 2 15 2* 16 3* 15 2** 15 2***
Initial PCr recovery rate 27 4 18 2* 19 4 15 1 18 2*
(mM min-')
Q. (mM min') 38 5 28 3* 27 6 22 2 26 3*
Initial proton efflux rate 7 1 3 1* 4 2 3 1 3 1
(mM min ')
Number of studies 13 10 7 3 11
in group
The overall half-times for metabolite recovery are shown. Data obtained immediately following
exercise cessation were used to calculate the rate of PCr recovery, proton efflux and calculated
mitochondrial capacity(Q,,.,). Resultsaredisplayed asmean ± s.e.m. forallstudiesineachcategory.
Student's paired t-test compared values from each individual's post-bryostatin study with their
pre-bryostatin study (control) (*P(0.05, **P(0.01, ***P(0.001). Each timed groupcontains no
more than onestudy from eachpatient. Themyalgia group consists ofall thestudiesobtained inthe
presence ofmyalgia and includes single data sets from three patients and two data sets from four
patients.
,D_
g 30-
25
g20
0)
x 10-
0
Control 4 h 48 - 72 h
(n = 5) (n= 4) (n= 3)
Figure 1 Effect of bryostatin I upon muscle reoxygenation half-
time, obtained from near-infrared spectroscopy 'Runman'. Data
points represent the overall mean ± s.e.m. for all available studies
in each category.
calculated initial proton efflux was significantly reduced by
54 ± 17% at 4 h following bryostatin, despite not reaching
significance in the myalgic group.
Thus differences in recovery after exercise were mainly at
4 h after dosing, whereas changes in PDE/ATP were maximal
at 24-48 h and associated with pain. In general, results for
those with myalgia were similar to 48-72 h results.
Near infra-red spectroscopy
Figure 1 suggests an increase in reoxygenation half-time at
4 h post-bryostatin (when it was higher than control in three
out of four patients), which by 48-72 h had returned to its
original value. The result did not reach statistical significance,
presumably because of the small number ofpatients in whom
this investigation was performed.
Discussion
Muscle pain and energy metabolism
In healthy muscle, various noxious stimuli will activate mus-
cle nociceptors, resulting in the perception of muscle pain
(Mills and Edwards, 1983). In pathologically altered muscle,
however, substances such as bradykinin, prostaglandin E2
and 5-hydroxytryptamine are released together and interact
with other factors such as catecholamines and hypoxia (Kies-
chke et al., 1988) to lower the mechanical threshold of
nociceptors, so that relatively weak stimuli can produce pain
(Mense, 1990). It has been suggested that nociceptors are
sensitised by defects in muscle energy metabolism originating
from the insufficient generation of ATP to preserve mem-
brane function, thus allowing substances such as potassium
to leak out of cells and so sensitise the nociceptors (Henriks-
son, 1988).
Owing to the carcinogenic nature of other PKC activators
such as the phorbol esters, human muscle studies with these
drugs have not been possible. Despite this, PKC activation
results in the release of factors thought to sensitise nocicep-
tors, by stimulating prostaglandin production and histamine
and serotonin release in muscle (Naka et al., 1983; Halenda
et al., 1985; Mobley and Tai, 1985). In the perfused rat heart
model we have found that bryostatin 1 lowers tissue ATP
and PCr levels as well as cell pH, possibly as a result of its
potent vasoconstricting actions (PF Hickman and K Clarke,
unpublished data). Thus we sought evidence in vivo that the
PKC-activating agent bryostatin 1 affects skeletal muscle
bioenergetics, in association with either primary or secondary
vasoconstriction.
Bioenergetics, bloodflow and 31P MRS
As PCr recovery occurs entirely as a result of mitochondrial
ATP synthesis under the influence of its regulator ADP, the
recovery kinetics of [PCr] and of [ADP] are good indices of
mitochondrial function (Kemp and Radda, 1994). There are
theoretical reasons why the ADP recovery half-time is a more
sensitive index of mitochondrial abnormallties than the PCr
recovery half-time (Kemp and Radda, 1994). The best quan-
titative estimate of the size of a functional defect in
mitochondrial capacity (either primary or secondary to
impaired supply of substrate or oxygen) is the calculated
mitochondrial capacity (Q.a) (Kemp and Radda, 1994;
Kemp et al., 1993b).
We find a reduced PCr resynthesis rate and a reduced Q.
at 4 h post bryostatin and in the myalgic group, associated
with slow ADP recovery at 48 h and 1-2 weeks post-
bryostatin and in the myalgic group (Table IV). These results
are consistent with impaired mitochondrial function follow-
ing bryostatin administration in both the presence and
absence ofmyalgia. This could in principle be due to either a
direct toxic effect on the mitochondria or impaired substrate
and oxygen supply as a result of vasoconstriction.
Activators of PKC in smooth muscle bring about contrac-
tion following phosphorylation of the myosin light chain
kinase (Naka et al., 1983). Although no work has been
published on the effects of bryostatin on smooth muscle, we
have recently found that, in the isolated perfused rat heart,
bryostatin 1 (like the PKC-activating phorbol esters; Kar-
mazyn et al., 1990) has a dose-dependent coronary vasocon-
striction action that is prevented by inhibition of PKC (PF
Hickman and K Clarke, unpublished data). Thus, a vaso-
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constrictive action might be expected in humans following
bryostatin, tending to reduce muscle blood flow and resulting
in impaired delivery of oxygen and substrate and washout of
metabolites, as is seen in patients with peripheral vascular
disease (Hands et al., 1986). In particular, reduced washout
from the extracellular space would inhibit net proton efflux,
as we found in the 4 h studies (Table IV). These results are in
contrast to those from both genetic and drug-induced
mitochondrial myopathies, which display a rapid pH re-
covery, probably as a result of increased proton efflux
(Arnold et al., 1985; Weissman et al., 1992). These findings
are complemented by the near-infrared spectroscopy studies,
which suggest a reduction of the rate of reoxygenation foll-
owing ischaemic exercise for 4 h after bryostatin administra-
tion (Figure 1).
Direct toxic effects on muscle
The phosphodiesters glycerophosphocholine and glycero-
phosphoethanolamine accumulate in dystrophic muscle and
in old age (Edwards et al., 1982), and this is possibly due to
membrane damage. Phorbol esters cause reversible destruc-
tion of myofibrils in differentiated muscle cells after 24-48 h
of incubation (Doetschman and Eppenberger, 1984). We
detected a significant increase in the PDE/ATP ratio in
patients 48 h following bryostatin and when experiencing
myalgia (Table II). If myofibrillar destruction is PKC
mediated, then the raised PDE/ATP ratio may reflect a direct
toxic effect of bryostatin upon muscle, which may require
further evaluation with muscle biopsies.
In conclusion, we have demonstrated two effects of bryo-
statin treatment on muscle metabolism in vivo during
recovery from exercise. First, there is a reduction in
mitochondrial function and, secondly, the effective proton
efflux is reduced. The simplest hypothesis is a reduction in
muscle blood flow subsequent to muscle vasoconstriction,
which is consistent with the probable reduced reoxygenation
rate we observed after ischaemic exercise, and with the effects
of bryostatin and other PKC activators in the perfused heart.
Bryostatin may also possess direct toxic effects, suggested by
the third observation, namely a rise in PDE/ATP in resting
muscle. Bryostatin has detectable effects on muscle cell
biochemistry and physiology in vivo. The change most clearly
associated with myalgia is the PDE/ATP ratio, which is
compatible with pain in resting muscle. The biphasic effects
at 4 h and 48 h may reflect in vivo modulation of PKC, with
initial transient stimulation followed by prolonged down-
regulation. Attempts to prevent the initial early change
should now be undertaken using vasodilators prospectively,
and such a study has been initiated using nifedipine. This
study demonstrates the unusual toxicities that may be
associated with novel anti-cancer drugs and methods that
may be needed to optimise their use.
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